Literature DB >> 10547569

Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.

J L Jones1, P Glynn, R A Walker.   

Abstract

Enhanced expression of the type IV collagenases MMP-2 and MMP-9, or lack of their inhibitors TIMP-1 and TIMP-2, has been associated with tumour invasion and metastatic potential in several experimental models. Regulation of enzyme activity is clearly a key step in tumour invasion, and recently a potent activator of MMP-2, the membrane-associated MT1-MMP, has been described and characterized. Using an immunohistochemical approach, this study has examined the expression and distribution of the type IV collagenases, their inhibitors, and the activator MT1-MMP, in a series of 79 infiltrating ductal carcinomas (IDCs), 8 tubular carcinomas, and 27 infiltrating lobular carcinomas (ILCs). MMP-2 and MT1-MMP were expressed in more than 90 per cent of all carcinomas, with predominantly stromal and tumour cell cytoplasmic staining. However, reactivity localized on tumour cell membranes was recorded for MMP-2 in 34 per cent of cases with a monoclonal antibody and 55 per cent of cases with a polyclonal antibody, and for MT1-MMP in 68 per cent of tumours. In each case, this pattern of staining was significantly associated with the presence of lymph node metastasis (p=0.001, p=0. 008, and p=0.1, respectively). Both tumour cell and stromal staining was observed for TIMP-2, but there was no correlation with metastatic status. The 92 kD gelatinase MMP-9 was expressed by 68 per cent of carcinomas, either in the stromal compartment or by tumour cells. There was a highly significant correlation between the expression pattern of MMP-9 and tumour type, with ILCs displaying greater frequency and more homogeneous cytoplasmic staining than IDCs (p=0.0004). Staining for TIMP-1 was seen in the stroma and also in relation to small blood vessels, with more than 90 per cent of tumours showing this staining pattern using a polyclonal antibody. This study indicates distinct patterns of expression for different MMPs and demonstrates the potential importance of the MMP-2/MT1-MMP system in breast tumour progression. The association of MMP-9 with the infiltrating lobular phenotype may reveal novel mechanisms of control for this metalloproteinase. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547569     DOI: 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  61 in total

1.  Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe.

Authors:  Walter J Akers; Baogang Xu; Hyeran Lee; Gail P Sudlow; Gregg B Fields; Samuel Achilefu; W Barry Edwards
Journal:  Bioconjug Chem       Date:  2012-02-29       Impact factor: 4.774

2.  Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.

Authors:  Odete Mendes; Hun-Taek Kim; George Stoica
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment.

Authors:  Heath B Acuff; Kathy J Carter; Barbara Fingleton; D Lee Gorden; Lynn M Matrisian
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

4.  Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer.

Authors:  Mauricio P Pinto; Melanie M Badtke; Michelle L Dudevoir; J Chuck Harrell; Britta M Jacobsen; Kathryn B Horwitz
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

5.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

6.  Similar expression profiles of a core of genes and proteins in cells that have acquired a metastatic phenotype, genetically or by in vivo evolution.

Authors:  Laila Illán Rubio; Bertrand Tavitian; Elina Zueva
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

7.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

8.  Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw.

Authors:  V Thumbigere-Math; B S Michalowicz; E P de Jong; T J Griffin; D L Basi; P J Hughes; M L Tsai; K K Swenson; L Rockwell; R Gopalakrishnan
Journal:  Oral Dis       Date:  2013-11-29       Impact factor: 3.511

9.  Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C.

Authors:  Tobias N Dechow; Laura Pedranzini; Andrea Leitch; Kenneth Leslie; William L Gerald; Irina Linkov; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

10.  Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.

Authors:  Rita C S Figueira; Luciana R Gomes; João S Neto; Fabricio C Silva; Ismael D C G Silva; Mari C Sogayar
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.